Tonerg was launched in Italy for treatment of acute and post traumatic stress
syndrome and "burnout" syndrome. It inhibits hypothalamic release of corticotropinreleasing
factor (CRF) and effectively antagonizes the activation of CRF induced
stress (neuroendocrine, autonomic and behavior responses). Tonerg is an atypical
antidepressant because it does not involve the monoaminergic system and differs in
effect from benzodiazepines (complete opposite effect of Diazepam). The entire
molecule is responsible for activity. It is lipophilic, orally bioavailable, and has a halflife
of 4-6 hr. Tonerg has a positive effect on sleep disorders by reducing insomnia,
improving anxiety by 20% and depression by 23%.
